Join
Live feed
·
PRReleasevia Quantisnow
TG Therapeutics Inc. logo

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

ByQuantisnow·Wall Street's wire, on your screen.
TGTX· TG Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TGTX (TG Therapeutics Inc.) and more on Quantisnow.